Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113087742 | 11308774 | 2 | F | 201309 | 20160719 | 20150724 | 20160725 | EXP | JP-ASTELLAS-2015JP015569 | ASTELLAS | 8.00 | DEC | F | Y | 0.00000 | 20160725 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 113087742 | 11308774 | 1 | SS | LIPITOR | ATORVASTATIN CALCIUM | 1 | Oral | UNK, UNK, UNKNOWN FREQ. | Y | 0 | FORMULATION UNKNOWN | ||||||||
| 113087742 | 11308774 | 2 | PS | TACROLIMUS. | TACROLIMUS | 1 | Oral | U | 50708 | 1.5 | MG | CAPSULE | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 113087742 | 11308774 | 1 | Dyslipidaemia |
| 113087742 | 11308774 | 2 | Immune-mediated necrotising myopathy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 113087742 | 11308774 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 113087742 | 11308774 | Immune-mediated necrotising myopathy | |
| 113087742 | 11308774 | Off label use |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 113087742 | 11308774 | 1 | 2010 | 201309 | 0 | |
| 113087742 | 11308774 | 2 | 20141119 | 0 |